Overview

A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

Status:
WITHDRAWN

Trial end date:
2025-06-10

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to see how well and how safely bimagrumab, tirzepatide, and the combination, work in lowering body weight in participants with obesity or overweight and type 2 diabetes. Participation in the study will last about 13 months.

Phase:

PHASE2

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

bimagrumab
Tirzepatide